Head of Portfolio Strategy
Chris works at the intersection of the discovery and investments teams on targets and portfolio strategy. He also leads efforts in building data-driven approaches to integrate genomics with computational physics to speed design in early drug discovery. Chris was chief of research and development at Silicon Therapeutics prior to its acquisition by Roivant Sciences.
Chris has held research leadership positions at pharmaceutical companies and emerging biotech companies, building and guiding high performing teams, bringing new medicines to patients in need, including 11 clinical phase medicines. Chris served as head of discovery biology in oncology at Sanofi and became site lead in 2015. He joined Sanofi from Blueprint Medicines, where he served as head of biology. The first biologist recruited to Blueprint, led and collaborated in building the team and drug discovery projects that became successful clinical programs. Prior to Blueprint, Chris held senior research positions at Merck Research Laboratories and Exelixis, Inc.
He received a doctor of philosophy degree in biochemistry & molecular biophysics from Columbia University in New York and was a post-doctoral fellow in the department of biological sciences at Stanford University in Stanford, Calif.